More on IOVA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.23 |
|
|||
| Open | $2.26 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.50 | ||||
| Day Low | $2.22 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 24,862,133 | ||||
- Form SCHEDULE 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: BlackRock, Inc.
- Form 8-K IOVANCE BIOTHERAPEUTICS, For: Jul 15
- Iovance Biotherapeutics names Corleen Roche as chief financial officer
- Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
- Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)
- Goldman Sachs Double Downgrades Iovanace Biotherapeutics (IOVA) to Sell
- Iovance reports 49% response rate for Amtagvi in melanoma study
- Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
- Iovance Biotherapeutics Sued for Securities Law Violations - Investors Should Contact Faruqi & Faruqi for More Information - IOVA
- IOVA 3-DAY DEADLINE ALERT: Hagens Berman Reminds Iovance (IOVA) Investors of Pending Securities Class Action, Encourages Investors with Losses to Contact the Firm
Entities mentioned with iova
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- 13G | View Related Stories »
- Show More...
